Developer docs
API playgroundTry for free, no card

Search company profiles

DIAN DIAGNOSTICS GROUP CO., LTD.

Full company profile

uuid004cps2

Namestring
DIAN DIAGNOSTICS GROUP CO., LTD.
Legal namestring
DIAN DIAGNOSTICS Group Co., Ltd.
Websiteurl
en.dazd.cn
Company typeenum
Public
Founded yearint
1996
Descriptiontext

DIAN Diagnostics Group Co., Ltd. is a Chinese independent clinical laboratory (ICL) operator and diagnostic product manufacturer headquartered in Hangzhou, Zhejiang, and listed on the Shenzhen Stock Exchange GEM (stock code 300244) since July 2011. The company runs an integrated "product + service" model that combines proprietary diagnostic kits and instruments (including DP-TOF mass spectrometry, LC-MS/MS systems, and HPV kits) with a national network of nearly 40 medical laboratories and 400+ collaborative laboratory projects deployed across 31 Chinese provinces. Customers include more than 22,000 medical institutions, with 90%+ coverage of secondary and tertiary hospitals in its core operating region and 60%+ of partner facilities classified as tertiary hospitals.

The company operates a high-throughput platform processing approximately 250,000 samples per day across 4,500+ diagnostic parameters, supported by 168 domestic and foreign qualifications and ISO 15189 implementation across 200+ hospitals. Its technology stack includes an AI-assisted digital pathology diagnosis solution (PathoAI, launched October 2022), virtual autopsy tools (Diangio & Aiangio), forensic services through 8 institutions, a health management arm (DIAN Healthcare), and cold chain logistics. A 10 PB clinical and pathology database underpins its AI and analytics work.

DIAN generates revenue through a combination of fee-for-service diagnostic testing on a volume basis, revenue-share arrangements with hospitals under collaborative laboratory agreements, and product sales of its proprietary instruments and kits. Long-standing partnerships with major industry players -- including Roche Diagnostics, Foundation Medicine, SCIEX/Danaher, Agena Bioscience, Phenomenex, and Johns Hopkins University -- reinforce the international component of its product and standards portfolio. The company has signaled international expansion through a Vietnam subsidiary (April 2024), a Malaysia representative office, a Gulf Medical University partnership in the UAE (January 2024), and existing operations in Germany and Australia.

Short descriptiontext

DIAN Diagnostics is a Chinese integrated diagnostic services and product manufacturer operating ~40 labs across 31 provinces, serving 22,000+ medical institutions with 250,000 daily samples across 4,500+ parameters and a proprietary AI pathology platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHangzhou, China
HQ citystring
Hangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical diagnostic services, clinical laboratory testing, molecular diagnostics platforms, mass spectrometry diagnostics, digital pathology diagnostics
Industry5 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACALAL
Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYTLALABAH
Medical Devices & Diagnostics Temperature-Controlled Storage
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Medical Diagnostic Services
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model7 records
1Diagnostic Services
TypeProfessional Services
Description

Medical diagnostic services through nearly 40 medical laboratories network serving 22,000+ medical institutions with daily sample size of 250,000.

en.dazd.cn
2Diagnostic Product Manufacturing
TypeHardware Sales
Description

Manufacturing and distribution of diagnostic products including laboratory supplies, kits, and instruments through channel subsidiaries.

3Health Management
TypeSubscription Recurring
Description

One-stop health management services from DIAN Healthcare covering physical examination, precision medicine, chronic disease treatment, and sub-health management.

4Forensic Services
TypeProfessional Services
Description

Third-party forensic institute with eight forensics chain institutions in China providing independent forensic services and products.

5Medical Cold Chain Logistics
TypeManaged Services
Description

Cold chain storage and distribution services for medical devices, medicines, diagnostic and biological products through Zhejiang DIAN Shenhai Cold-Chain Logistics Co., Ltd.

6Collaborative Laboratory Services
TypeProfessional Services
Description

Consultation, management, and technical services for hospital testing centers and laboratories with over 400 collaborative projects.

7Investment Returns
TypeManaged Services
Description

ZJH FUND (RMB 10 billion target fund) focusing on healthcare investments with Phase 1 RMB 1 billion completed, two projects listed on stock market.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1GENEDIAN
Description

International brand of DIAN Biotechnology for diagnostic products and services, operating in Europe, Australia and Southeast Asia.

en.dazd.cn
+5 more records
Core offering1 text field

DIAN Diagnostics Group is an integrated medical diagnostics provider that delivers clinical diagnostic services through a network of nearly 40 medical laboratories serving more than 22,000 medical institutions in China with daily capacity for 250,000 samples. Alongside its service business, the company develops, manufactures and sells proprietary diagnostic products including the DP-TOF Nucleic Acid Mass Spectrometry Solution, LC MS/MS Solution, AI-Assisted Digital Pathology Diagnosis Solution, laboratory supplies and kits, and a Forensic Drug Test Solution. The offering is rounded out by health management services and a dedicated cold-chain logistics subsidiary (Zhejiang DIAN Shenhai).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 45 million+ cervical cancer cell pathological tests and 15 million+ HPV DNA tests completed
+3 more records
Product overview1 text field

DIAN DIAGNOSTICS GROUP CO., LTD. operates as an integrated medical diagnostics platform with 'product + service' architecture. The company offers: (1) AI-Assisted Digital Pathology Diagnosis Solution for integrated digital pathology; (2) DP-TOF Nucleic Acid Mass Spectrometry Solution as China's first approved general-purpose nucleic acid mass spectrometer; (3) LC MS/MS Solution for biomarker identification; (4) comprehensive Forensic Drug Test Solutions including handheld detectors and immunoassay kits; (5) Laboratory Supplies and Kits including cryogenic storage and diagnostic reagents; and (6) diagnostic services through nearly 40 medical laboratories. The portfolio includes CALIBRA Precision Medicine subsidiary for clinical mass spectrometry, DIAN Biotechnology (GENEDIAN brand) for IVD products, DIAN Healthcare for health management, DIAN FORENSICS for forensic services, and cold chain logistics operations. The company serves over 22,000 medical institutions with over 4,500 diagnostic parameters.

Product and service2 records
1Medical Diagnostic Laboratory Services
CategoryMedical Diagnostic Services
Description

Outsourced clinical diagnostic testing services delivered through a national network of nearly 40 medical laboratories to hospitals, clinics, and medical institutions across China, with daily capacity of 250,000 samples.

2DP-TOF Nucleic Acid Mass Spectrometry Solution
Scale indicator26 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-17
Description

Dian Diagnostics signed Letter of Intent for Cooperation with Gulf Medical University for academic and research collaboration.

2European MLM Medical Lab
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-05-07
Description

Teddy Lab reached strategic cooperation with European MLM medical lab to contribute to international pharmaceutical research and development.

en.dazd.cn
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-03-31
Description

Deepening and expanding international cooperation with medical centre visits and academic exchange.

4Zhejiang Pathology Specialty Alliance
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

DIAN DIAGNOSTICS participated in the establishment of Zhejiang Pathology Specialty Alliance in 2019.

en.dazd.cn
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-07-04
Description

DIAN partnered with Agena for mass spectrometry platform development and applications in clinical diagnostics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

DIAN joined hands with Roche Diagnostics to introduce comprehensive genome sequencing analysis service for jointly promoting the progression of individualized diagnosis and treatment of tumor in China.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-01-01
Description

DIAN joined hands with Roche and FMI to introduce comprehensive genome sequencing analysis service for tumor diagnosis and treatment in China.

8Zhejiang Laboratory and Testing Sharing Platform Specialty Alliance
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

DIAN DIAGNOSTICS participated in the establishment of Zhejiang Laboratory and Testing Sharing Platform Specialty Alliance in 2019.

en.dazd.cn
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

International Pathology Consultation Center established for pathology consultation services bridging US and China expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.

11Baida Group
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

DIAN DIAGNOSTICS jointly held the Dian-Hopkins Forum together with Johns Hopkins University six times since 2015. In 2017, DIAN DIAGNOSTICS established its International Pathology Consultation Center in collaboration with Johns Hopkins University for international pathology expertise sharing.

Strategic tierCoreTypeTechnology or Integration
Description

CALIBRA Precision Medicine, a subsidiary of DIAN DIAGNOSTICS, maintains close strategic cooperation with SCIEX, a global mass spectrometry leader. Together they work on R&D and production of clinical mass spectrometers and reagents, multi-omics innovation and other fields.

Strategic tierCoreTypeTechnology or Integration
Description

CALIBRA Precision Medicine maintains strategic cooperation with Phenomenex, a separation science and technology innovator, for clinical mass spectrometry R&D and production.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest Chinese medical device and IVD instrumentation manufacturer; overlaps with DIAN's IVD reagent and instrument business (PCR, mass spec, pathology scanners) as a broader incumbent with far greater scale.

TypeOthers
Description

Mass spectrometry platform provider for clinical genomics, already a partner of DIAN. Ecosystem participant and technology enabler rather than direct competitor, but relevant for benchmarking DIAN's DP-TOF and Agena-based assay strategy.

TypeDirect peer
Description

China's largest independent medical laboratory network, directly comparable in operating a national chain of clinical labs serving hospitals with routine and esoteric diagnostic testing. Closest domestic analog in business model and customer base.

TypeDirect peer
Description

Global genomics and molecular diagnostics operator with strong NIPT, oncology, and infectious disease testing franchises. Overlaps with DIAN's sequencing-based oncology and maternal/child health diagnostics.

TypeBroad incumbent
Description

International medical diagnostics operator with lab networks across Australia, Europe, and the US; comparable in operating multi-country lab services and partnering with hospital systems, relevant to DIAN's international expansion strategy.

TypeBroad incumbent
Description

Largest US independent clinical laboratory network with extensive routine and esoteric testing menus; comparable in scale and breadth of diagnostic services, with similar enterprise sales motion to hospitals and physicians.

TypeBroad incumbent
Description

Global clinical laboratory and diagnostics company; comparable in central-lab operating model, breadth of test menu, and companion diagnostics capabilities competing for the same hospital outsourcing decisions.

8WuXi Diagnostics
TypeEmerging player
Description

China-focused integrated diagnostics platform combining clinical labs with IVD R&D, comparable to DIAN's product+service model but with a younger footprint and stronger focus on hospital-side partnership models.

TypeDirect peer
Description

Leading Chinese molecular diagnostics company with PCR, NAAT, and clinical lab services across infectious disease and oncology. Directly competes with DIAN's molecular IVD and central lab offerings in China.

TypeBroad incumbent
Description

Diversified Chinese healthcare conglomerate with a meaningful diagnostics and IVD business, comparable in offering integrated diagnostic services and products but operating across a much wider therapeutic footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment9 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance18 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DIAN DIAGNOSTICS GROUP CO., LTD.

Medical Diagnostic Servicesen.dazd.cn

DIAN Diagnostics is a Chinese integrated diagnostic services and product manufacturer operating ~40 labs across 31 provinces, serving 22,000+ medical institutions with 250,000 daily samples across 4,500+ parameters and a proprietary AI pathology platform.

What DIAN DIAGNOSTICS GROUP CO., LTD. does

DIAN Diagnostics Group Co., Ltd. is a Chinese independent clinical laboratory (ICL) operator and diagnostic product manufacturer headquartered in Hangzhou, Zhejiang, and listed on the Shenzhen Stock Exchange GEM (stock code 300244) since July 2011. The company runs an integrated "product + service" model that combines proprietary diagnostic kits and instruments (including DP-TOF mass spectrometry, LC-MS/MS systems, and HPV kits) with a national network of nearly 40 medical laboratories and 400+ collaborative laboratory projects deployed across 31 Chinese provinces. Customers include more than 22,000 medical institutions, with 90%+ coverage of secondary and tertiary hospitals in its core operating region and 60%+ of partner facilities classified as tertiary hospitals.

The company operates a high-throughput platform processing approximately 250,000 samples per day across 4,500+ diagnostic parameters, supported by 168 domestic and foreign qualifications and ISO 15189 implementation across 200+ hospitals. Its technology stack includes an AI-assisted digital pathology diagnosis solution (PathoAI, launched October 2022), virtual autopsy tools (Diangio & Aiangio), forensic services through 8 institutions, a health management arm (DIAN Healthcare), and cold chain logistics. A 10 PB clinical and pathology database underpins its AI and analytics work.

DIAN generates revenue through a combination of fee-for-service diagnostic testing on a volume basis, revenue-share arrangements with hospitals under collaborative laboratory agreements, and product sales of its proprietary instruments and kits. Long-standing partnerships with major industry players -- including Roche Diagnostics, Foundation Medicine, SCIEX/Danaher, Agena Bioscience, Phenomenex, and Johns Hopkins University -- reinforce the international component of its product and standards portfolio. The company has signaled international expansion through a Vietnam subsidiary (April 2024), a Malaysia representative office, a Gulf Medical University partnership in the UAE (January 2024), and existing operations in Germany and Australia.

DIAN DIAGNOSTICS GROUP CO., LTD. firmographics

Firmographics
Name
DIAN DIAGNOSTICS GROUP CO., LTD.
Legal name
DIAN DIAGNOSTICS Group Co., Ltd.
Website
https://en.dazd.cn
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
1–10 employees
Short description
DIAN Diagnostics is a Chinese integrated diagnostic services and product manufacturer operating ~40 labs across 31 provinces, serving 22,000+ medical institutions with 250,000 daily samples across 4,500+ parameters and a proprietary AI pathology platform.
Ownership category
akta.pro rank

DIAN DIAGNOSTICS GROUP CO., LTD. industry classification

Industry
Product category
Medical Diagnostic Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACALAL
Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYTLALABAH
Medical Devices & Diagnostics Temperature-Controlled Storage

Keywords

  • Medical diagnostic services
  • Clinical laboratory testing
  • Molecular diagnostics platforms
  • Mass spectrometry diagnostics
  • Digital pathology diagnostics

Where DIAN DIAGNOSTICS GROUP CO., LTD. is headquartered

Location

Headquarters

HQ city
Hangzhou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

DIAN DIAGNOSTICS GROUP CO., LTD. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Services: Medical diagnostic services through nearly 40 medical laboratories network serving 22,000+ medical institutions with daily sample size of 250,000.
  2. Diagnostic Product Manufacturing: Manufacturing and distribution of diagnostic products including laboratory supplies, kits, and instruments through channel subsidiaries.
  3. Health Management: One-stop health management services from DIAN Healthcare covering physical examination, precision medicine, chronic disease treatment, and sub-health management.
  4. Forensic Services: Third-party forensic institute with eight forensics chain institutions in China providing independent forensic services and products.
  5. Medical Cold Chain Logistics: Cold chain storage and distribution services for medical devices, medicines, diagnostic and biological products through Zhejiang DIAN Shenhai Cold-Chain Logistics Co., Ltd.
  6. Collaborative Laboratory Services: Consultation, management, and technical services for hospital testing centers and laboratories with over 400 collaborative projects.
  7. Investment Returns: ZJH FUND (RMB 10 billion target fund) focusing on healthcare investments with Phase 1 RMB 1 billion completed, two projects listed on stock market.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels5 records

DIAN DIAGNOSTICS GROUP CO., LTD. product offering

Product offering

Core offering

DIAN Diagnostics Group is an integrated medical diagnostics provider that delivers clinical diagnostic services through a network of nearly 40 medical laboratories serving more than 22,000 medical institutions in China with daily capacity for 250,000 samples. Alongside its service business, the company develops, manufactures and sells proprietary diagnostic products including the DP-TOF Nucleic Acid Mass Spectrometry Solution, LC MS/MS Solution, AI-Assisted Digital Pathology Diagnosis Solution, laboratory supplies and kits, and a Forensic Drug Test Solution. The offering is rounded out by health management services and a dedicated cold-chain logistics subsidiary (Zhejiang DIAN Shenhai).

Product overview

DIAN DIAGNOSTICS GROUP CO., LTD. operates as an integrated medical diagnostics platform with 'product + service' architecture. The company offers: (1) AI-Assisted Digital Pathology Diagnosis Solution for integrated digital pathology; (2) DP-TOF Nucleic Acid Mass Spectrometry Solution as China's first approved general-purpose nucleic acid mass spectrometer; (3) LC MS/MS Solution for biomarker identification; (4) comprehensive Forensic Drug Test Solutions including handheld detectors and immunoassay kits; (5) Laboratory Supplies and Kits including cryogenic storage and diagnostic reagents; and (6) diagnostic services through nearly 40 medical laboratories. The portfolio includes CALIBRA Precision Medicine subsidiary for clinical mass spectrometry, DIAN Biotechnology (GENEDIAN brand) for IVD products, DIAN Healthcare for health management, DIAN FORENSICS for forensic services, and cold chain logistics operations. The company serves over 22,000 medical institutions with over 4,500 diagnostic parameters.

Differentiator

Problem solved

Functional benefit

Brands

  • GENEDIAN: International brand of DIAN Biotechnology for diagnostic products and services, operating in Europe, Australia and Southeast Asia.
  • SayFine
  • CALIBRA
  • DIAN Healthcare
  • DIAN FORENSICS
  • Medical Mall

Products and services

  • Medical Diagnostic Laboratory Services Outsourced clinical diagnostic testing services delivered through a national network of nearly 40 medical laboratories to hospitals, clinics, and medical institutions across China, with daily capacity of 250,000 samples.
  • DP-TOF Nucleic Acid Mass Spectrometry Solution

Quantifiable outcome

  • 45 million+ cervical cancer cell pathological tests and 15 million+ HPV DNA tests completed
  • +3 more outcomes

Companies that use DIAN DIAGNOSTICS GROUP CO., LTD.

Customer profile

Named customers5 records

Segments9 records

Ideal customer profiles2 records

DIAN DIAGNOSTICS GROUP CO., LTD. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

DIAN DIAGNOSTICS GROUP CO., LTD. partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered minor, core and flagship.

  • Gulf Medical UniversityminorStrategic or Co-development Partner · 17 January 2024Dian Diagnostics signed Letter of Intent for Cooperation with Gulf Medical University for academic and research collaboration.
  • European MLM Medical LabminorStrategic or Co-development Partner · 7 May 2019Teddy Lab reached strategic cooperation with European MLM medical lab to contribute to international pharmaceutical research and development.
  • University of Malaya Medical CentreminorStrategic or Co-development Partner · 31 March 2019Deepening and expanding international cooperation with medical centre visits and academic exchange.
  • Zhejiang Pathology Specialty AllianceminorStrategic or Co-development Partner · 1 January 2019DIAN DIAGNOSTICS participated in the establishment of Zhejiang Pathology Specialty Alliance in 2019.
  • Agena BiosciencecoreTechnology or Integration · 4 July 2018DIAN partnered with Agena for mass spectrometry platform development and applications in clinical diagnostics.
  • Roche DiagnosticscoreStrategic or Co-development Partner · 1 January 2018DIAN joined hands with Roche Diagnostics to introduce comprehensive genome sequencing analysis service for jointly promoting the progression of individualized diagnosis and treatment of tumor in China.
  • Foundation Medicine (FMI)coreTechnology or Integration · 1 January 2018DIAN joined hands with Roche and FMI to introduce comprehensive genome sequencing analysis service for tumor diagnosis and treatment in China.
  • Zhejiang Laboratory and Testing Sharing Platform Specialty AllianceminorStrategic or Co-development Partner · 1 January 2018DIAN DIAGNOSTICS participated in the establishment of Zhejiang Laboratory and Testing Sharing Platform Specialty Alliance in 2019.
  • Johns Hopkins University - International Pathology Consultation CentercoreStrategic or Co-development Partner · 1 January 2017International Pathology Consultation Center established for pathology consultation services bridging US and China expertise.
  • Jiebai GroupcoreStrategic or Co-development Partner · 1 January 2016Three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.
  • Baida GroupcoreStrategic or Co-development Partner · 1 January 2016Three listed companies - DIAN DIAGNOSTICS, Jiebai Group and Baida Group - jointly established the Medical Mall, the first integrated health care and retail business mall in China.
  • Johns Hopkins UniversityflagshipStrategic or Co-development Partner · 1 January 2015DIAN DIAGNOSTICS jointly held the Dian-Hopkins Forum together with Johns Hopkins University six times since 2015. In 2017, DIAN DIAGNOSTICS established its International Pathology Consultation Center in collaboration with Johns Hopkins University for international pathology expertise sharing.
  • SCIEX (Danaher Group)coreTechnology or IntegrationCALIBRA Precision Medicine, a subsidiary of DIAN DIAGNOSTICS, maintains close strategic cooperation with SCIEX, a global mass spectrometry leader. Together they work on R&D and production of clinical mass spectrometers and reagents, multi-omics innovation and other fields.
  • PhenomenexcoreTechnology or IntegrationCALIBRA Precision Medicine maintains strategic cooperation with Phenomenex, a separation science and technology innovator, for clinical mass spectrometry R&D and production.

Scale indicators26 records

Recent moves8 records

Expansion highlights6 records

DIAN DIAGNOSTICS GROUP CO., LTD. competitors and assessment

Company assessment

Broad incumbents

  • Mindray: Largest Chinese medical device and IVD instrumentation manufacturer; overlaps with DIAN's IVD reagent and instrument business (PCR, mass spec, pathology scanners) as a broader incumbent with far greater scale.
  • Sonic Healthcare: International medical diagnostics operator with lab networks across Australia, Europe, and the US; comparable in operating multi-country lab services and partnering with hospital systems, relevant to DIAN's international expansion strategy.
  • Quest Diagnostics: Largest US independent clinical laboratory network with extensive routine and esoteric testing menus; comparable in scale and breadth of diagnostic services, with similar enterprise sales motion to hospitals and physicians.
  • Laboratory Corporation of America (Labcorp): Global clinical laboratory and diagnostics company; comparable in central-lab operating model, breadth of test menu, and companion diagnostics capabilities competing for the same hospital outsourcing decisions.
  • Shanghai Fosun Pharmaceutical (Diagnostics arm): Diversified Chinese healthcare conglomerate with a meaningful diagnostics and IVD business, comparable in offering integrated diagnostic services and products but operating across a much wider therapeutic footprint.

Others

  • Agena Bioscience: Mass spectrometry platform provider for clinical genomics, already a partner of DIAN. Ecosystem participant and technology enabler rather than direct competitor, but relevant for benchmarking DIAN's DP-TOF and Agena-based assay strategy.

Direct peers

  • KingMed Diagnostics: China's largest independent medical laboratory network, directly comparable in operating a national chain of clinical labs serving hospitals with routine and esoteric diagnostic testing. Closest domestic analog in business model and customer base.
  • BGI Genomics: Global genomics and molecular diagnostics operator with strong NIPT, oncology, and infectious disease testing franchises. Overlaps with DIAN's sequencing-based oncology and maternal/child health diagnostics.
  • DaAn Gene (Da An Gene): Leading Chinese molecular diagnostics company with PCR, NAAT, and clinical lab services across infectious disease and oncology. Directly competes with DIAN's molecular IVD and central lab offerings in China.

Emerging players

  • WuXi Diagnostics: China-focused integrated diagnostics platform combining clinical labs with IVD R&D, comparable to DIAN's product+service model but with a younger footprint and stronger focus on hospital-side partnership models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DIAN DIAGNOSTICS GROUP CO., LTD. social profiles

Digital presence

DIAN DIAGNOSTICS GROUP CO., LTD. compliance and trust

Trust signal

Compliance18 records

DIAN DIAGNOSTICS GROUP CO., LTD. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DIAN DIAGNOSTICS GROUP CO., LTD. leadership team

Management profile

Number of profiles

Profiles1 record

DIAN DIAGNOSTICS GROUP CO., LTD. subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

DIAN DIAGNOSTICS GROUP CO., LTD. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DIAN DIAGNOSTICS GROUP CO., LTD. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIAN DIAGNOSTICS GROUP CO., LTD.

What does DIAN DIAGNOSTICS GROUP CO., LTD. do?

DIAN Diagnostics Group is an integrated medical diagnostics provider that delivers clinical diagnostic services through a network of nearly 40 medical laboratories serving more than 22,000 medical institutions in China with daily capacity for 250,000 samples. Alongside its service business, the company develops, manufactures and sells proprietary diagnostic products including the DP-TOF Nucleic Acid Mass Spectrometry Solution, LC MS/MS Solution, AI-Assisted Digital Pathology Diagnosis Solution, laboratory supplies and kits, and a Forensic Drug Test Solution. The offering is rounded out by health management services and a dedicated cold-chain logistics subsidiary (Zhejiang DIAN Shenhai).

Is DIAN DIAGNOSTICS GROUP CO., LTD. a public or private company?

DIAN DIAGNOSTICS GROUP CO., LTD. is a public company. It is classified as public and is currently operating.

When was DIAN DIAGNOSTICS GROUP CO., LTD. founded?

DIAN DIAGNOSTICS GROUP CO., LTD. was founded in 1996. It employs 1 to 10 people.

Where is DIAN DIAGNOSTICS GROUP CO., LTD. based?

DIAN DIAGNOSTICS GROUP CO., LTD. is headquartered in Hangzhou, China, in the Asia region.

How does DIAN DIAGNOSTICS GROUP CO., LTD. make money?

Seven revenue lines are on record. Diagnostic Services are the primary driver. The others are diagnostic Product Manufacturing, health Management, forensic Services, medical Cold Chain Logistics, collaborative Laboratory Services and investment Returns.

Who are DIAN DIAGNOSTICS GROUP CO., LTD.'s main competitors?

Broad incumbents on record are Mindray, Sonic Healthcare, Quest Diagnostics, Laboratory Corporation of America (Labcorp) and Shanghai Fosun Pharmaceutical (Diagnostics arm). Agena Bioscience is listed as an others. Direct peers are KingMed Diagnostics, BGI Genomics and DaAn Gene (Da An Gene). WuXi Diagnostics is listed as an emerging player.

Does DIAN DIAGNOSTICS GROUP CO., LTD. have an API?

No public API is recorded for DIAN DIAGNOSTICS GROUP CO., LTD..

What industry is DIAN DIAGNOSTICS GROUP CO., LTD. in?

DIAN DIAGNOSTICS GROUP CO., LTD.'s product category is Medical Diagnostic Services. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals